Viewing Study NCT04369300



Ignite Creation Date: 2024-05-06 @ 2:36 PM
Last Modification Date: 2024-10-26 @ 1:34 PM
Study NCT ID: NCT04369300
Status: UNKNOWN
Last Update Posted: 2020-07-15
First Post: 2020-04-28

Brief Title: Anxiety And Depression During COVID-19 IN INDIA
Sponsor: Max Healthcare Insititute Limited
Organization: Max Healthcare Insititute Limited

Study Overview

Official Title: Prevalence Of Anxiety And Depression During COVID-19
Status: UNKNOWN
Status Verified Date: 2020-07
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: 1 To understand the prevalence of symptoms of Depression and Anxiety in general population during COVID-19 in India
2 To understand correlation between COVID-19 related factors and mental health symptomology in the general population in India

Hypothesis

There is likelihood of significant symptoms of depression and anxiety among general population in India during the current COVID-19 outbreak

Procedure

The participants would be selected with their informed consent The objective of the study would be clearly written on Page 1 of the survey The test would be administered electronically by all the participants individually only when consented to the study The data collected will be kept strictly confidential and the identity of the participants will not be disclosed at any point of the research

Measures

1 Demographic Information Demographic variables included Gender Age Place of Stay Marital Status Highest Level ofEducation current living arrangement eg staying alone or with family and Occupation It further includesregular employment status and current employment statuseg Work from home temporary leave termination etc
2 History of illness Present or past History of physical ailment specified diabetes hypertension heart ailment or being on any steroid or any other chronic ailment Previous history of H1N1 Influenza like illness
3 COVID-19 Information This section includes time spent focusing on COVID related information current stressors with respect to COVID-19 and coping mechanisms used This further includesinformation on resources available to participants near their place of stay and information of any known diagnosed case of COVID-19
4 Standardized Scales to be used Generalized Anxiety Disorder Scale GAD-7 Patient Health Questionnaire PHQ-9 Powered by
Detailed Description: Aim

1 To understand the prevalence of symptoms of Depression and Anxiety in general population during COVID-19 in India
2 To understand correlation between COVID-19 related factors and mental health symptomology in the general population in India

Hypothesis

There is likelihood of significant symptoms of depression and anxiety among general population in India during the current COVID-19 outbreak

Procedure

The participants would be selected with their informed consent The objective of the study would be clearly written on Page 1 of the survey The test would be administered electronically by all the participants individually only when consented to the study The data collected will be kept strictly confidential and the identity of the participants will not be disclosed at any point of the research

Measures

1 Demographic Information Demographic variables included Gender Age Place of Stay Marital Status Highest Level of Education current living arrangement eg staying alone or with family and Occupation It further includes regular employment status and current employment statuseg Work from home temporary leave termination etc
2 History of illness Present or past History of physical ailment specified diabetes hypertension heart ailment or being on any steroid or any other chronic ailment Previous history of H1N1 Influenza like illness
3 COVID-19 Information This section includes time spent focusing on COVID related information current stressors with respect to COVID-19 and coping mechanisms used This further includes information on resources available to participants near their place of stay and information of any known diagnosed case of COVID-19
4 Standardized Scales to be used Generalized Anxiety Disorder Scale GAD-7 Patient Health Questionnaire PHQ-9

Primary outcome To understand the prevalence magnitude of depression and anxiety of general adult population during COVID-19 using Generalized Anxiety Disorder Scale GAD-7 and Patient Health Questionnaire PHQ-9 Rise in Anxiety and Depression will be noted

Through the analysis of the results help device psychological interventionmental health programs geared towards general and specific symptoms and management of emotional needs can be provided to the general population during and post-crisis

Secondary Outcome Through the analysis of the results it will help device psychological interventionmental health programs geared towards general and specific symptoms and management of emotional needs can be provided to the general population during and post-crisis

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None